Autonomix Medical, Inc.
AMIXHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Autonomix Medical, Inc. (AMIX) is listed under Medical Devices. At a $4.7M market cap, Autonomix Medical, Inc. ranks as a micro-cap company within healthcare. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system.
Market Cap
$4.7M
Beta
-0.94
P/E (TTM)
—
P/E (Fwd)
-0.33
EPS (TTM)
$-39.67
EPS (Fwd)
$-7.40
ROE
-316.0%
ROA
-157.8%
Cash
$3.5M
Total Debt
$0
Free CF
-$7.6M
52W Change
-89.8%
Annual Financials
Cash vs Debt
Where AMIX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AMIX finished 59.54% below its 150-day moving average ($6.55) and 63.04% below its 200-day moving average ($7.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMIX overbought or oversold?
At the October 20, 2026 close, AMIX's RSI(14) was 13.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Autonomix Medical, Inc. reports $3.5M in cash and $0 in total debt. Free cash flow is running at -$7.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -316.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
AMIX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing AMIX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.